Innocoll Announces Dosing Of First Patient In US Phase 2 Clinical Trial To Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT
Jan 5th 2008Drug InformationClinical Trials
Innocoll, Inc., a privately-held specialty pharmaceutical company, announced that the first of a series of planned phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the management of post operative pain, has commenced dosing.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
